berbamine has been researched along with Osteosarcoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Han, X; Hang, K; Hu, H; Li, J; Li, W; Li, Y; Tian, W; Xin, Z; Xu, R; Zhao, J | 1 |
Horne, DA; Jove, R; Liu, L; Nam, S; Tian, Y; Yang, F; Zhao, R | 1 |
2 other study(ies) available for berbamine and Osteosarcoma
Article | Year |
---|---|
2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; NF-kappa B; Osteosarcoma; Proto-Oncogene Proteins c-akt | 2020 |
A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling.
Topics: Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Bone Neoplasms; Caspase 3; Cell Line, Tumor; Cell Survival; Cyclin D1; Cyclin D2; Humans; JNK Mitogen-Activated Protein Kinases; Osteosarcoma; Phosphorylation; Reactive Oxygen Species; Signal Transduction; Transcription Factor AP-1 | 2013 |